SG11201408076WA - Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide - Google Patents

Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Info

Publication number
SG11201408076WA
SG11201408076WA SG11201408076WA SG11201408076WA SG11201408076WA SG 11201408076W A SG11201408076W A SG 11201408076WA SG 11201408076W A SG11201408076W A SG 11201408076WA SG 11201408076W A SG11201408076W A SG 11201408076WA SG 11201408076W A SG11201408076W A SG 11201408076WA
Authority
SG
Singapore
Prior art keywords
international
ylmethylamino
quinazolin
sulfonamide
pyridin
Prior art date
Application number
SG11201408076WA
Other languages
English (en)
Inventor
Jayakumar S Warrier
Navnath Dnyanoba Yadev
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201408076WA publication Critical patent/SG11201408076WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201408076WA 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide SG11201408076WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Publications (1)

Publication Number Publication Date
SG11201408076WA true SG11201408076WA (en) 2015-01-29

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408076WA SG11201408076WA (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Country Status (34)

Country Link
US (1) US9238666B2 (da)
EP (1) EP2858987B1 (da)
JP (1) JP6234450B2 (da)
KR (1) KR102092984B1 (da)
CN (1) CN104350048B (da)
AR (1) AR091402A1 (da)
AU (1) AU2013274619B2 (da)
BR (1) BR112014030629B1 (da)
CA (1) CA2876359C (da)
CL (1) CL2014003361A1 (da)
CO (1) CO7160032A2 (da)
CY (1) CY1120432T1 (da)
DK (1) DK2858987T3 (da)
EA (1) EA024692B1 (da)
ES (1) ES2675314T3 (da)
HK (1) HK1203928A1 (da)
HR (1) HRP20180815T8 (da)
HU (1) HUE039210T2 (da)
IL (1) IL236074A (da)
LT (1) LT2858987T (da)
MX (1) MX356699B (da)
MY (1) MY169219A (da)
NZ (1) NZ703632A (da)
PE (1) PE20150228A1 (da)
PH (1) PH12014502747B1 (da)
PL (1) PL2858987T3 (da)
PT (1) PT2858987T (da)
RS (1) RS57376B1 (da)
SG (1) SG11201408076WA (da)
SI (1) SI2858987T1 (da)
TN (1) TN2014000499A1 (da)
TW (1) TWI571470B (da)
WO (1) WO2013188254A1 (da)
ZA (1) ZA201500161B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970294B1 (en) * 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9458164B2 (en) * 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
US20180318268A1 (en) * 2015-11-19 2018-11-08 Biohaven Pharmaceutical Holding Company Ltd. Amine prodrugs of pharmaceutical compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE69940063D1 (de) 1998-07-06 2009-01-22 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
KR20070092297A (ko) * 2004-12-21 2007-09-12 데브젠 엔브이 Kv4 이온 채널 활성을 갖는 화합물
ES2750598T3 (es) * 2009-09-03 2020-03-26 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
AU2011270701B2 (en) * 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
EP2970199A1 (en) * 2013-03-11 2016-01-20 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
PH12014502747A1 (en) 2015-02-02
US20150175641A1 (en) 2015-06-25
CL2014003361A1 (es) 2015-05-29
SI2858987T1 (en) 2018-06-29
ES2675314T3 (es) 2018-07-10
IL236074A (en) 2016-08-31
KR20150023667A (ko) 2015-03-05
NZ703632A (en) 2016-01-29
HUE039210T2 (hu) 2018-12-28
KR102092984B1 (ko) 2020-03-24
TWI571470B (zh) 2017-02-21
MY169219A (en) 2019-03-19
EP2858987B1 (en) 2018-04-25
RS57376B1 (sr) 2018-08-31
CY1120432T1 (el) 2019-07-10
HRP20180815T8 (hr) 2019-02-08
JP2015521598A (ja) 2015-07-30
EA024692B1 (ru) 2016-10-31
AU2013274619B2 (en) 2017-09-28
BR112014030629B1 (pt) 2021-12-21
DK2858987T3 (da) 2018-07-30
PH12014502747B1 (en) 2015-02-02
JP6234450B2 (ja) 2017-11-22
PL2858987T3 (pl) 2018-08-31
IL236074A0 (en) 2015-02-01
ZA201500161B (en) 2017-04-26
LT2858987T (lt) 2018-07-10
MX2014014525A (es) 2015-02-24
CN104350048B (zh) 2016-12-07
PE20150228A1 (es) 2015-02-19
EP2858987A1 (en) 2015-04-15
MX356699B (es) 2018-06-11
AR091402A1 (es) 2015-02-04
US9238666B2 (en) 2016-01-19
CA2876359A1 (en) 2013-12-19
HK1203928A1 (en) 2015-11-06
CO7160032A2 (es) 2015-01-15
AU2013274619A1 (en) 2015-01-29
HRP20180815T1 (hr) 2018-06-29
BR112014030629A2 (pt) 2017-06-27
TW201402592A (zh) 2014-01-16
TN2014000499A1 (en) 2016-03-30
WO2013188254A1 (en) 2013-12-19
CA2876359C (en) 2020-01-21
EA201492256A1 (ru) 2016-05-31
CN104350048A (zh) 2015-02-11
PT2858987T (pt) 2018-07-04

Similar Documents

Publication Publication Date Title
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201407533SA (en) Antiviral compounds
SG11201408094YA (en) Neprilysin inhibitors
CA2859619C (en) Bromodomain inhibitors
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201805927YA (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
SG11201407115XA (en) Carboxylic acid compounds
SG11201408261UA (en) Syringe
SG11201408791TA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201408160TA (en) Phosphinyl guanidine compounds, metal salt complexes, catalyst systems, and their use to oligomerize or polymerize olefins
SG11201408539UA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407189XA (en) C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407372UA (en) Nampt inhibitors
SG11201408629QA (en) Dimethyl-benzoic acid compounds